摘要
目的探讨半胱氨酸蛋白酶抑制剂C(Cys C)及其相关肾小球滤过率(GFR)估计值(e GFR)计算方程在糖尿病患者肾脏功能评价中的应用价值。方法收集110例2型糖尿病患者资料,依据m GFR将患者分为代偿组和中重度损伤组,了解不同组别患者的基本情况,分析Scr、Cys C以及不同的e GFR公式与m GFR的相关性。结果全部患者、代偿组和中重度损害组的患者在与m GFR进行相关性比较时,Cys C(r全部患者=-0.661,r代偿组=-0.795,r中重度损害组=-0.420)较SCr(r全部患者=-0.593,r代偿组=-0.657,r中重度损害组=-0.380)均表现出更好的相关性,以Cys C为基础的e GFR-EPICyc S计算的e GFR与m GFR之间的差异不具有统计学意义(P=0.804)。结论与Scr相较,Cys C在糖尿病患者肾功能评价中显示更高的应用价值,在对不同e GFR公式进行比较后本研究推荐e GFR-EPICys C对患者进行GFR的估计。
Objective To investigate the clinical value of Cystatin C and its use in evaluation of renal function in patients with type 2 diabetes mellitus. Methods A total of 110 diabetic patients were divided into two groups based on measured Glomemlar Filtration Rate （mGFR）, compensatory group and moderate or severe injury group. The levels of Scr and CysC were compared between two groups. Results When compared with mGFR in all Patients, compensatory group and moderate or severe injury group, the correlations of CysC/mGFR were r = -0.661, r = -0.795 and r = -0.420 repectively, which showed better correlation than Scr （ r = -0. 593, r = -0. 657, r = -0.380）. No statistical differences were found among the groups （P = 0. 804） when using eGFR-EPIcycs. Conclusion When compared with Scr, CysC showed better clinical value in the evaluation of renal function in patients with type 2 diabetes, and the eGFR-EPIcycs was recommended for estimating of renal function.
出处
《标记免疫分析与临床》
CAS
2016年第6期600-602,共3页
Labeled Immunoassays and Clinical Medicine
